Digital biomarkers that remotely monitor symptoms have the potential to revolutionize
outcome assessments in future disease-modifying trials in Parkinson's disease (PD), by …

Automated online cognitive assessments are set to revolutionise clinical research and
healthcare. However, their applicability for Parkinson's Disease (PD) and REM Sleep …

This paper examines the use of digital endpoints (DEs) derived from digital health
technologies (DHTs), focusing primarily on the specific considerations regarding the …

Sensor data from digital health technologies (DHTs) used in clinical trials provides a
valuable source of information, because of the possibility to combine datasets from different …

Introduction Digital health technologies (DHTs) driven by artificial intelligence applications,
particularly those including predictive models derived with machine learning methods, have …

Introduction Parkinson's Disease affects over 8.5 million people and there are currently no
medications approved to treat underlying disease. Clinical trials for disease modifying …

Recently proposed digital measures of Parkinson's disease are gaining momentum. 1, 2
More objective, more precise, and more easily repeated than human expert-based …

Background: Parkinson Disease (PD) is a progressive neurological disorder. Current
therapeutic trials investigate treatments that can potentially modify the disease course …

Parkinson's Disease (PD) is the second most common neurodegenerative disorder globally,
and current screening methods often rely on subjective evaluations. We developed deep …

Recently, the Digital Medicine Society (DiMe) updated their three-component framework to
evaluate if a DHT is fit for purpose. The framework initially covered Verification, Analytical …